Home › Companies › ERAS

Erasca

Market cap $4.87B 351.0M shares (10-Q, Nov 5, 2026) × $13.89 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. ERAS-4001 Ph1 interim2H 2026ERAS-4001 Ph1 interim, 2H 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Discontinued (4)

Capital (as filed)

Cash
$119M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$525M Sep 30, 2026
Long-term investments
$304M Sep 30, 2026
Operating cash flow
−$32.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$948M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Erasca, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Erasca (ERAS): Scientific Deep Dive for Lead and Pipeline Products Superior potency (20x tighter CypA binding) and cash runway to 2029 create an attractive risk/reward in smid-cap biotech with strong M&A appeal.
  2. Speculative buy speculative UPDATE: Erasca (ERAS) - A Free Look at a Rational Combo Tango PRMT5 combo deal de-risks the pipeline further and strengthens M&A appeal without additional cash burn, keeping the speculative BUY thesis intact.
  3. Speculative buy speculative UPDATE: Erasca (ERAS) - Burns the Boats and Goes All-In on RAS Killing Naporafenib and buying global ERAS-0015 rights cleans up the story as a pure-play RAS company, keeping the speculative BUY thesis intact despite a shortened runway.
  4. Hold UPDATE: Erasca (ERAS) - The Clock is Set for Mid-May Thesis intact but 58% run-up into binary catalyst warrants holding rather than adding; existing holders should consider trimming partials to lock in gains while keeping a core position for the readout.
  5. Hold UPDATE: Erasca (ERAS) - The Data Lands, and So Does the Lawsuit Threat Science track is on with accelerated cohort initiation, but RevMed cease-and-desist opens a legal track that taxes M&A premium; thesis bifurcated pending full data deck and legal developments.
  6. Avoid UPDATE: Erasca (ERAS) - A Buried Phase 1 Fatality and the Rapid Collapse of ERAS-0015 Grade 5 fatal pneumonitis at the recommended expansion dose shatters the pristine-safety differentiation thesis, while RevMed trade-secret litigation freezes M&A prospects.
  7. Avoid UPDATE: Erasca (ERAS) - A $150M Mea Culpa and a Merck Wrinkle Safety break and litigation overhang unchanged; Merck CTCSA is a real counter-signal but not a thesis breaker; next data event is 12 months away.
  8. Watch UPDATE: Erasca (ERAS) - The Data Rehabilitates, and Management Raises $500M Anyway Expanded safety table with 72 patients at PAD shows differentiated low-grade tox profile and panitumumab combo cleared first cohort, partially rehabilitating the thesis, but RevMed litigation overhang and $500M raise cap near-term upside.
  9. Watch UPDATE: Erasca (ERAS) - They Just Hired the Pancreatic Cancer Guy Hiring former Roche/Genentech global oncology development head with pancreatic cancer expertise is a genuine positive for execution probability but does not resolve RevMed litigation or advance the next data inflection.
  10. Watch UPDATE: Erasca (ERAS) - The FDA Just Answered a Question I Had Been Asking Since April FDA granting Fast Track Designation with a Grade 5 in the file is soft de-risking of the regulatory track, but RevMed litigation and H1 2027 data inflection remain the two unresolved thesis gates.
  11. Watch UPDATE: Erasca (ERAS) - The Fine Print Before Barcelona Non-clinical signals now mixed (insider sale plans, class action, discounted raise) alongside solid balance sheet; ENA plenary data in six days will determine whether confirmed responses and safety table warrant an upgrade or return to AVOID.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (35)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)